22 completed, 5 terminated, 2 unknown, 2 withdrawn. 20 Phase 2, 10 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 13, Terminated 4, Withdrawn 2, Unknown 1 |
| Phase 1 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Stage III Melanoma: new trials by email Literature Review of Stage III Melanoma trials Research Report on Stage III Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021 Stage III Melanoma | Recruiting | University Hospital, Strasbourg, France | 221 | 2024-12-11 | 2025-12-24 | |
| Sargramostim (GM-CSF) + PD-1 Sargramostim (GM-CSF), Pembrolizumab (anti-PD-1) - Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2021-04-16 | 2023-05-22 | |
| Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting Stage III Melanoma, Stage IV Cutaneous Melanoma | Completed | Case Comprehensive Cancer Center | 73 | 2019-10-01 | 2024-07-29 | |
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab - Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Phase 2 | Completed | Emory University | 15 | 2019-06-05 | 2026-10-02 |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors TBX-3400 - Stage III Melanoma, Stage IV Melanoma | Phase 1 | Unknown | Taiga Biotechnologies, Inc. | 72 | 2019-06-02 | 2022-05-03 |
| TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma Trametinib, Dabrafenib - Stage IV Melanoma, Stage III Melanoma | Phase 2 | Completed | Universitair Ziekenhuis Brussel | 45 | 2019-01-28 | 2023-09-26 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 26 | 2017-10-31 | 2024-10-01 |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma IMP321 (eftilagimod alpha), Pembrolizumab - Stage IV Melanoma, Stage III Melanoma | Phase 1 | Completed | Immutep Australia Pty. Ltd. | 24 | 2016-04-01 | 2019-12-18 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma | Phase 2 | Completed | St. Louis University | 10 | 2015-01-01 | 2019-06-20 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC) - Stage IV Melanoma, Stage III Melanoma | Phase 3 | Terminated | Lisata Therapeutics, Inc. | 4 | 2014-10-01 | 2019-05-10 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| Interferon Toxicities in Melanoma Treatment Stage III Melanoma | Completed | Bristol-Myers Squibb | 436 | 2014-05-01 | 2016-06-09 | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations BRAF inhibitor dabrafenib and MEK inhibitor trametinib - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 17 | 2013-04-04 | 2020-11-23 |
| Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma Ofatumumab, Ofatumumab plus Dacarbazine - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | Medical University of Vienna | 10 | 2011-06-01 | 2015-10-06 |
| Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma MKC1106-MT - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Terminated | Mannkind Corporation | 5 | 2010-10-01 | 2012-05-15 |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Pazopanib and Paclitaxel - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | University of California, Irvine | 60 | 2010-08-01 | 2019-08-07 |
| Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. Nilotinib - Malignant Skin Melanoma T0, Stage III Melanoma | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 25 | 2010-07-01 | 2011-02-08 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery ziv-aflibercept, pharmacological study - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-06-01 | 2018-05-24 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2006-04-01 | 2015-04-15 |
Showing 20 of 32. Sign in to see all of them.
Melanoma (32) · Neoplasms (3) · Skin Neoplasms (3) · Breast Neoplasms (2) · Breast Neoplasms, Male (2) · Carcinoma, Renal Cell (2) · Carcinoma, Ovarian Epithelial (1) · Colonic Neoplasms (1) · Esthesioneuroblastoma, Olfactory (1) · Prostatic Neoplasms (1) · Recurrence (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms by Histologic Type (32) · Neoplasms by Site (32) · Neoplasms, Germ Cell and Embryonal (32) · Neoplasms, Nerve Tissue (32) · Neuroectodermal Tumors (32) · Neuroendocrine Tumors (32) · Nevi and Melanomas (32) · Skin Diseases (32) · Skin and Connective Tissue Diseases (32) · Neoplasms (29) · Skin Neoplasms (29) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Urogenital Diseases (3)
pembrolizumab (5) · Sorafenib (3) · Allovectin-7 (2) · Dacarbazine (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Ipilimumab (2) · Nivolumab (2) · Sirolimus (2) · sargramostim (2) · temsirolimus (2) · 1-methyltryptophan (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · Amifostine (1) · Azacitidine (1) · Bevacizumab (1)
National Cancer Institute (NCI) (12) · Vical (2) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Immutep Australia Pty. Ltd. (1) · Lisata Therapeutics, Inc. (1) · Mannkind Corporation (1) · Medical University of Vienna (1) · NewLink Genetics Corporation (1) · St. Louis University (1) · Taiga Biotechnologies, Inc. (1)
United States (23) · France (2) · Australia (1) · Austria (1) · Belgium (1)
Kevin Kim (3) · Ahmad Tarhini (1) · Anna Pavlick (1) · Bart Neyns, MD, PhD (1) · Carrie Lee, MD (1) · Celeste Lebbe, MD, PhD (1) · Cherie Smith (1) · David Solit (1) · Douglas Fraker (1) · Elizabeth Buchbinder, MD (1) · James Isaacs, MD (1) · Jeffrey Weber (1) · Jennifer Fernandez (1)
PMID 21206909, PMID 26837440, PMID 29943192, PMID 39374099, PMID 42640721
N01CM62202 (3), 2015 (1), K12CA076930 (1), N01CM62204 (1), N01CM62206 (1), N01CM62209 (1), P30CA016672 (1), P30CA033572 (1), R21CA137647 (1), U01CA062505 (1), U01CA069856 (1), U10CA076001 (1)